Cargando…
Japan’s Ongoing Crisis on HPV Vaccination
The Japanese government suspended proactive recommendations for the HPV vaccine in June 2013. The suspension is now in its seventh year, despite all the data pointing to the safety of the HPV vaccine. We reported a high vaccine effectiveness in the group of women vaccinated before their first interc...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565470/ https://www.ncbi.nlm.nih.gov/pubmed/32640691 http://dx.doi.org/10.3390/vaccines8030362 |
_version_ | 1783595939969105920 |
---|---|
author | Sekine, Masayuki Kudo, Risa Yamaguchi, Manako J. B. Hanley, Sharon Hara, Megumi Adachi, Sosuke Ueda, Yutaka Miyagi, Etsuko Ikeda, Sayaka Yagi, Asami Enomoto, Takayuki |
author_facet | Sekine, Masayuki Kudo, Risa Yamaguchi, Manako J. B. Hanley, Sharon Hara, Megumi Adachi, Sosuke Ueda, Yutaka Miyagi, Etsuko Ikeda, Sayaka Yagi, Asami Enomoto, Takayuki |
author_sort | Sekine, Masayuki |
collection | PubMed |
description | The Japanese government suspended proactive recommendations for the HPV vaccine in June 2013. The suspension is now in its seventh year, despite all the data pointing to the safety of the HPV vaccine. We reported a high vaccine effectiveness in the group of women vaccinated before their first intercourse (93.9%). The prevalence of cross-protected types of HPV 31/45/52 was also lower in the vaccinated group, and the vaccine effectiveness was 67.7%. Furthermore, prevalence of HPV16, 31 and 52 infection rates in the vaccinated group were obviously lower than that in the unvaccinated group, and no one had HPV18 or 45 infection in the vaccinated group. The addition of a cross-protective effect toward HPV types 31/45/52 to HPV types 16/18, which is the direct target of the bivalent HPV vaccine, may possibly prevent around 82% of invasive cervical cancer cases in Japan. With regard to the preventive effect of histological abnormalities, we also reported significant reduction in incidence of cervical intraepithelial neoplasia (CIN)3 or worse. Thus, the efficacy of the vaccine has been demonstrated for precancerous disease, and the diverse symptoms after HPV vaccination are likely functional somatic. For the future of Japanese girls, there is a need to resume the proactive recommendation of HPV vaccination and for immediate action to be taken by the Japanese government. |
format | Online Article Text |
id | pubmed-7565470 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75654702020-10-26 Japan’s Ongoing Crisis on HPV Vaccination Sekine, Masayuki Kudo, Risa Yamaguchi, Manako J. B. Hanley, Sharon Hara, Megumi Adachi, Sosuke Ueda, Yutaka Miyagi, Etsuko Ikeda, Sayaka Yagi, Asami Enomoto, Takayuki Vaccines (Basel) Review The Japanese government suspended proactive recommendations for the HPV vaccine in June 2013. The suspension is now in its seventh year, despite all the data pointing to the safety of the HPV vaccine. We reported a high vaccine effectiveness in the group of women vaccinated before their first intercourse (93.9%). The prevalence of cross-protected types of HPV 31/45/52 was also lower in the vaccinated group, and the vaccine effectiveness was 67.7%. Furthermore, prevalence of HPV16, 31 and 52 infection rates in the vaccinated group were obviously lower than that in the unvaccinated group, and no one had HPV18 or 45 infection in the vaccinated group. The addition of a cross-protective effect toward HPV types 31/45/52 to HPV types 16/18, which is the direct target of the bivalent HPV vaccine, may possibly prevent around 82% of invasive cervical cancer cases in Japan. With regard to the preventive effect of histological abnormalities, we also reported significant reduction in incidence of cervical intraepithelial neoplasia (CIN)3 or worse. Thus, the efficacy of the vaccine has been demonstrated for precancerous disease, and the diverse symptoms after HPV vaccination are likely functional somatic. For the future of Japanese girls, there is a need to resume the proactive recommendation of HPV vaccination and for immediate action to be taken by the Japanese government. MDPI 2020-07-06 /pmc/articles/PMC7565470/ /pubmed/32640691 http://dx.doi.org/10.3390/vaccines8030362 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Sekine, Masayuki Kudo, Risa Yamaguchi, Manako J. B. Hanley, Sharon Hara, Megumi Adachi, Sosuke Ueda, Yutaka Miyagi, Etsuko Ikeda, Sayaka Yagi, Asami Enomoto, Takayuki Japan’s Ongoing Crisis on HPV Vaccination |
title | Japan’s Ongoing Crisis on HPV Vaccination |
title_full | Japan’s Ongoing Crisis on HPV Vaccination |
title_fullStr | Japan’s Ongoing Crisis on HPV Vaccination |
title_full_unstemmed | Japan’s Ongoing Crisis on HPV Vaccination |
title_short | Japan’s Ongoing Crisis on HPV Vaccination |
title_sort | japan’s ongoing crisis on hpv vaccination |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565470/ https://www.ncbi.nlm.nih.gov/pubmed/32640691 http://dx.doi.org/10.3390/vaccines8030362 |
work_keys_str_mv | AT sekinemasayuki japansongoingcrisisonhpvvaccination AT kudorisa japansongoingcrisisonhpvvaccination AT yamaguchimanako japansongoingcrisisonhpvvaccination AT jbhanleysharon japansongoingcrisisonhpvvaccination AT haramegumi japansongoingcrisisonhpvvaccination AT adachisosuke japansongoingcrisisonhpvvaccination AT uedayutaka japansongoingcrisisonhpvvaccination AT miyagietsuko japansongoingcrisisonhpvvaccination AT ikedasayaka japansongoingcrisisonhpvvaccination AT yagiasami japansongoingcrisisonhpvvaccination AT enomototakayuki japansongoingcrisisonhpvvaccination |